Strata Skin Sciences, Inc. (SSKN) — SEC Filings
Strata Skin Sciences, Inc. (SSKN) — 48 SEC filings. Latest: 10-K (Mar 26, 2026). Includes 32 8-K, 6 10-Q, 3 10-K.
View Strata Skin Sciences, Inc. on SEC EDGAR
Overview
Strata Skin Sciences, Inc. (SSKN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: STRATA Skin Sciences, Inc. (SSKN) focuses on dermatologic conditions with its XTRAC excimer lasers and VTRAC lamp systems, treating psoriasis, vitiligo, and other skin conditions. The company also offers the TheraClear X Acne Therapy System. As of December 31, 2025, 842 XTRAC systems were under the
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 6 bearish, 40 neutral, 2 mixed. The dominant filing sentiment for Strata Skin Sciences, Inc. is neutral.
Filing Type Overview
Strata Skin Sciences, Inc. (SSKN) has filed 3 10-K, 32 8-K, 6 10-Q, 2 DEF 14A, 2 10-K/A, 2 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of SSKN's 42 recent filings, 5 were flagged as high-risk, 14 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Dr. Dolev Rafaeli
- Uri Geiger
- Board of Directors
- Michael L. Culhane
- Dr. Robert E. Grant
Industry Context
STRATA Skin Sciences operates in the medical technology sector, specifically focusing on dermatologic treatments. The market for these devices is driven by the prevalence of skin conditions like psoriasis and vitiligo, and advancements in laser and light-based therapies. Key trends include the development of more efficient and targeted treatment systems and evolving reimbursement landscapes, which significantly influence adoption rates and revenue generation.
Top Tags
disclosure (13) · 8-K (11) · financials (11) · financial-reporting (6) · 10-Q (4) · corporate-governance (4) · Dermatology (3) · delisting (3) · corporate-filing (3) · 8-k (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of non-affiliate common equity | $3,699,213 | as of June 30, 2025, based on $2.29 per share |
| XTRAC systems in dermatology recurring procedures model | 842 | as of December 31, 2025, in the U.S. |
| Shares outstanding of common stock | 5,888,199 | as of March 16, 2026 |
| Effective date for revised CPT codes | 2027-01-01 | expanding excimer laser reimbursement indications |
| Insured population covered for XTRAC vitiligo treatments | 58% | as of December 31, 2025, in the U.S. |
| Minimum CPT code reimbursement per treatment | $137 | for 2025, for excimer laser treatments |
| Maximum CPT code reimbursement per treatment | $183 | for 2025, for excimer laser treatments |
| Efficacy rate of XTRAC excimer lasers | 89% | for psoriasis treatment |
| Target U.S. dermatologists | 3,500 | for XTRAC lasers who perform disease management |
| Year U.S. introduced trade policy actions | 2025 | increasing import tariffs |
| Net Revenues | $21.404M | Decreased from $23.986M in 2024 for the nine months ended September 30, 2025 |
| Net Loss | $6.319M | Increased from $5.531M in 2024 for the nine months ended September 30, 2025 |
| Cash and Cash Equivalents | $7.076M | As of September 30, 2025, down from $7.261M at December 31, 2024 |
| Restricted Cash | $1.3M | Executed by the State of New York during the nine months ended September 30, 2025 |
| XTRAC systems | 838 | Placed in dermatologists' offices in the United States as of September 30, 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Strata Skin Sciences, Inc. (SSKN)?
Strata Skin Sciences, Inc. has 48 recent SEC filings from Jan 2024 to Mar 2026, including 32 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SSKN filings?
Across 48 filings, the sentiment breakdown is: 6 bearish, 40 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Strata Skin Sciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Strata Skin Sciences, Inc. (SSKN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Strata Skin Sciences, Inc.?
Key financial highlights from Strata Skin Sciences, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SSKN?
The investment thesis for SSKN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Strata Skin Sciences, Inc.?
Key executives identified across Strata Skin Sciences, Inc.'s filings include Dr. Dolev Rafaeli, Uri Geiger, Board of Directors, Michael L. Culhane, Dr. Robert E. Grant.
What are the main risk factors for Strata Skin Sciences, Inc. stock?
Of SSKN's 42 assessed filings, 5 were flagged high-risk, 14 medium-risk, and 23 low-risk.
What are recent predictions and forward guidance from Strata Skin Sciences, Inc.?
Forward guidance and predictions for Strata Skin Sciences, Inc. are extracted from SEC filings as they are enriched.